Toxicity to intravitreal melphalan in a patient with retinoblastoma.
Rom J Ophthalmol
; 67(3): 305-308, 2023.
Article
en En
| MEDLINE
| ID: mdl-37876503
ABSTRACT
Objective:
Description of melphalan's toxicity in retinoblastoma treatment.Methods:
Clinical case report.Results:
We presented a case of unilateral retinoblastoma with vitreous seeding at diagnosis, in which the use of intravitreal melphalan produced many adverse reactions.Conclusions:
Vitreous seedings have been one of the most important challenges in retinoblastoma treatment. Intravitreal melphalan has achieved the regression of vitreous seedings in a large percentage of cases. It is a safe treatment; however, it can produce toxicity, even with the standard dose of 20-30 µg, which has been poorly documented. Exhaustive follow-up of patients is recommended for an early diagnosis of possible adverse effects. Abbreviations OS = left eye, RI = magnetic resonance imaging, OCT = optical coherence tomography.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Retinoblastoma
/
Neoplasias de la Retina
Límite:
Humans
Idioma:
En
Revista:
Rom J Ophthalmol
Año:
2023
Tipo del documento:
Article
País de afiliación:
España